Australia’s Parliament Shoots Down Pharma Cost Recovery Bill; Lilly Closes In On Diabetes Reimbursement In NZ: Australia/New Zealand Regulatory Roundup
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Medicines Australia applauded the defeat in Australia's parliament Aug. 28 of the National Health Amendment, which included a cost-recovery mechanism that would have put the onus on drug makers to fund the process for listing medicines on Australia's Pharmaceutical Benefits Scheme